Evox Therapeutics enters into agreement to advance next generation exosome-delivered AAV gene therapy for the treatment of heart disease

The agreement aims to tackle long-standing challenges in cardiovascular disease Oxford, UK, August 4, 2023 – Evox Therapeutics Ltd (‘Evox’), a leading exosome therapeutics company, today announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY. The collaboration will work on developing … Read more The post Evox Therapeutics enters into agreement to advance next generation exosome-delivered AAV gene therapy for the treatment of heart disease appeared first on Evox Therapeutics .